1
|
Belahnech Y, Martí Aguasca G, Dos Subirà L. Advances in Diagnostic and Interventional Catheterization in Adults with Fontan Circulation. J Clin Med 2024; 13:4633. [PMID: 39200775 PMCID: PMC11355634 DOI: 10.3390/jcm13164633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2024] [Revised: 07/19/2024] [Accepted: 08/05/2024] [Indexed: 09/02/2024] Open
Abstract
Over the past five decades, the Fontan procedure has been developed to improve the life expectancy of patients with congenital heart defects characterized by a functionally single ventricle. The Fontan circulation aims at redirecting systemic venous return to the pulmonary circulation in the absence of an impelling subpulmonary ventricle, which makes this physiology quite fragile and leads to several long-term complications. Despite the importance of hemodynamic assessment through cardiac catheterization in the management and follow-up of these patients, a thorough understanding of the ultimate functioning of this type of circulation is lacking, and the interpretation of the hemodynamic data is often complex. In recent years, new tools such as combined catheterization with cardiopulmonary exercise testing have been incorporated to improve the understanding of the hemodynamic profile of these patients. Furthermore, extensive percutaneous treatment options have been developed, addressing issues ranging from obstructive problems in Fontan pathway and acquired shunts through compensatory collaterals to the percutaneous treatment of lymphatic circulation disorders and transcatheter edge-to-edge repair of atrioventricular valves. The aim of this review is to detail the various tools used in cardiac catheterization for patients with Fontan circulation, analyze different percutaneous treatment strategies, and discuss the latest advancements in this field.
Collapse
Affiliation(s)
- Yassin Belahnech
- Adult Congenital Heart Disease Unit, Cardiology Department, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; (Y.B.); (G.M.A.)
| | - Gerard Martí Aguasca
- Adult Congenital Heart Disease Unit, Cardiology Department, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; (Y.B.); (G.M.A.)
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Laura Dos Subirà
- Adult Congenital Heart Disease Unit, Cardiology Department, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; (Y.B.); (G.M.A.)
- Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain
- European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart), Coordinating Center in Amsterdam, 1105 AZ Amsterdam, The Netherlands
| |
Collapse
|
2
|
Agorrody G, Begun I, Verma S, Mazer CD, Garagiola ML, Fernandez-Campos B, Acuña R, Kearney K, Buckley A, Dhingra NK, Ghamarian E, Roche SL, Alonso-Gonzalez R, Wald RM. Patient Reported Outcome Measures in Adults with Fontan Circulatory Failure. J Clin Med 2024; 13:4175. [PMID: 39064214 PMCID: PMC11277569 DOI: 10.3390/jcm13144175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2024] [Revised: 07/04/2024] [Accepted: 07/07/2024] [Indexed: 07/28/2024] Open
Abstract
Background: Patient reported outcomes (PROs) are important measures in acquired heart disease but have not been well defined in Adult Congenital Heart Disease (ACHD). Our aim was to explore the discriminatory capacity of PRO survey tools in Fontan circulatory failure (FCF). Methods: Consecutive adults were enrolled from our ambulatory clinics. Inclusion criteria were age ≥18 years, a Fontan circulation or a hemodynamically insignificant shunt lesion, and sufficient cognitive/language abilities to complete PROs. A comprehensive package of PRO measures, designed to assess perceived health-related quality of life (HRQOL) was administered (including the Kansas City Cardiomyopathy Questionnaire [KCCQ-12], EuroQol-5-dimension [EQ5D], Short Form Health Status Survey [SF-12], self-reported New York Heart Association [NYHA] Functional Class, and Specific Activity Scale [SAS]). Results: We compared 54 Fontan patients (35 ± 10 years) to 25 simple shunt lesion patients (34 ± 11 years). The KCCQ-12 score was lower in Fontan versus shunt lesion patients (87 [IQR 79, 95] versus 100 [IQR 97, 100], p-value < 0.001). The FCF subgroup was associated with lower KCCQ-12 scores as compared with the non-FCF subgroup (82 [IQR 56, 89] versus 93 [IQR 81, 98], p-value = 0.002). Although the KCCQ-12 had the best discriminatory capacity for determination of FCF of all PRO tools studied (c-statistic 0.75 [CI 0.62, 0.88]), superior FCF discrimination was achieved when the KCCQ-12 was combined with all PRO tools (c-statistic 0.82 [CI 0.71, 0.93]). Conclusions: The KCCQ-12 questionnaire demonstrated good discriminatory capacity for the identification of FCF, which was further improved through the addition of complementary PRO tools. Further research will establish the value of PRO tools to guide management strategies in ACHD.
Collapse
Affiliation(s)
- Guillermo Agorrody
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Isaac Begun
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Subodh Verma
- Division of Cardiac Surgery, Unity Health, St. Michael’s Hospital, University of Toronto, 585 University Avenue, Toronto, ON M5G 2N2, Canada (N.K.D.)
| | - C. David Mazer
- Department of Anaesthesia, Unity Health, St. Michael’s Hospital, University of Toronto, Toronto, ON M5S 1A1, Canada
| | - Maria Luz Garagiola
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Beatriz Fernandez-Campos
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Ronald Acuña
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Katherine Kearney
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Alvan Buckley
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Nitish K. Dhingra
- Division of Cardiac Surgery, Unity Health, St. Michael’s Hospital, University of Toronto, 585 University Avenue, Toronto, ON M5G 2N2, Canada (N.K.D.)
| | - Ehsan Ghamarian
- Applied Health Research Centre, Unity Health, St. Michael’s Hospital, University of Toronto, Toronto, ON M5S 1A1, Canada
| | - S. Lucy Roche
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Rafael Alonso-Gonzalez
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| | - Rachel M. Wald
- Toronto Adult Congenital Heart Disease Program, Peter Munk Cardiac Centre, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
| |
Collapse
|
3
|
Sánchez-Escobar IC, Aranzazu-Ceballos AD, Pérez LE, Guzmán MI. Fontan surgery failure: risk factors and experience in a Colombian reference centre. Cardiol Young 2024; 34:722-726. [PMID: 37743785 DOI: 10.1017/s1047951123003244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 09/26/2023]
Abstract
BACKGROUND The Fontan procedure is considered one of the most remarkable achievements in paediatric cardiology and cardiac surgery. Its final anatomical objective is a venous return through the superior and inferior vena cava. The complications inherent to this procedure and subsequent failure are its limitations. OBJECTIVE To describe the clinical and haemodynamic characteristics of patients with Fontan failure and define the risk factors associated with it, with its short- and long-term outcomes during a 21-year observation period. METHODS This is a retrospective follow-up study in which 15 patients diagnosed with Fontan failure in the single-ventricle programme of a high-complexity hospital in Medellín, Colombia, between 2001 and 2022 were included. RESULTS One hundred and eight patients were identified in whom the Fontan procedure was performed, and 17 met the failure criteria. 82.4% were men, with a median age of 4.3 years. Ebstein's anomaly was the most common diagnosis, 29.4%. All patients underwent Fontan with an extracardiac tube following the procedure. According to the type of failure, 58.8% of patients presented protein-losing enteropathy and 17.6% plastic bronchitis. During follow-up, 5.9% of patients died. CONCLUSION Fontan surgery in our centre is an option for patients with univentricular physiology. The correct selection of the patient is essential to mitigate failure risks.
Collapse
Affiliation(s)
- Isabel C Sánchez-Escobar
- Fellow Pediatric Cardiology, CardioVid Clinic, Pontifical Bolivarian University, Medellin, Colombia
| | - Andrés D Aranzazu-Ceballos
- Pediatrician, Faculty of Medicine, CardioVid Clinic, Universidad Pontificia Bolivariana, Medellin, Colombia
| | - Luz E Pérez
- Medical Epidemiologist, CardioVid Clinic, Medellin, Colombia
| | - Mónica I Guzmán
- Pediatric Cardiologist, CardioVid Clinic, Medellin, Colombia
| |
Collapse
|
4
|
Chowdhury UK, Anderson RH, Pandey NN, Mishra S, Sankhyan LK, George N, Khan MA, Goja S. The so-called "one-and-a-half" ventricular repair: where are we after 40 years? Cardiol Young 2023; 33:1497-1505. [PMID: 37394701 DOI: 10.1017/s1047951123001646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 07/04/2023]
Abstract
OBJECTIVES The indications, timing, and results of the so-called "one-and-a-half ventricle repair", as a surgical alternative to the creation of the Fontan circulation, or high-risk biventricular repair, currently remain nebulous. We aimed to clarify these issues. METHODS We reviewed a total of 201 investigations, assessing selection of candidates, the need for atrial septal fenestration, the fate of an unligated azygos vein and free pulmonary regurgitation, the concerns regarding reverse pulsatile flow in the superior caval vein, the growth potential and function of the subpulmonary ventricle, and the role of the superior cavopulmonary connections as an interstage procedure prior to biventricular repair, or as a salvage procedure. We also assessed subsequent eligibility for conversion to biventricular repair and long-term functional results. RESULTS Reported operative mortalities ranged from 3% to 20%, depending on the era of surgical repair with 7% risk of complications due to a pulsatile superior caval vein, up to one-third incidence of supraventricular arrhythmias, and a small risk of anastomotic takedown of the superior cavopulmonary connection. Actuarial survival was between 80% and 90% at 10 years, with two-thirds of patients in good shape after 20 years. We found no reported instances of plastic bronchitis, protein-losing enteropathy, or hepatic cirrhosis. CONCLUSIONS The so-called "one-and-a-half ventricular repair", which is better described as production of one-and-a-half circulations can be performed as a definitive palliative procedure with an acceptable risk similar to that of conversion to the Fontan circulation. The operation reduces the surgical risk for biventricular repair and reverses the Fontan paradox.
Collapse
Affiliation(s)
- Ujjwal Kumar Chowdhury
- Department of Cardiothoracic and Vascular Surgery, National Institute of Medical Sciences & Research, Jaipur, RJ, India
| | | | - Niraj Nirmal Pandey
- Cardiovascular Radiology and Endovascular Interventions, All India Institute of Medical Sciences, New Delhi, DL, India
| | - Sundeep Mishra
- Cardiology, National Institute of Medical Sciences & Research, Jaipur, RJ, India
| | - Lakshmi Kumari Sankhyan
- Department of Cardiothoracic and Vascular Surgery, All India Institute of Medical Sciences, Bilaspur, Bilaspur, CG, India
| | - Niwin George
- Department of Cardiothoracic and Vascular Surgery, Government Medical College, Thiruvananthapuram, Thiruvananthapuram, KL, India
| | - Maroof A Khan
- All India Institute of Medical Sciences, New Delhi, DL, India
| | - Shikha Goja
- Department of CTVS, All India Institute of Medical Sciences, New Delhi, DL, India
| |
Collapse
|
5
|
Thornton SW, Meza JM, Prabhu NK, Kang L, Moya-Mendez ME, Parker LE, Fleming GA, Turek JW, Andersen ND. Impact of Ventricular Dominance on Long-Term Fontan Outcomes: A 25-year Single-institution Study. Ann Thorac Surg 2023; 116:508-515. [PMID: 36543280 DOI: 10.1016/j.athoracsur.2022.11.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Revised: 11/14/2022] [Accepted: 11/28/2022] [Indexed: 12/23/2022]
Abstract
BACKGROUND The long-term impact of ventricular dominance on Fontan outcomes is controversial. This study examined this issue in a 25-year cohort. METHODS Patients undergoing the Fontan operation at a single institution (Duke University Medical Center, Durham, NC) from October 1998 to February 2022 were reviewed. Primary outcomes were transplant-free survival and Fontan failure (death, heart transplantation, takedown, protein-losing enteropathy, or plastic bronchitis). Secondary outcomes included hospital and intensive care lengths of stay. Kaplan-Meier methodology compared outcomes by ventricular dominance. Multiphase parametric risk hazard analysis identified risk factors for primary outcomes. RESULTS There were 195 patients (104 right ventricular dominant) included in the study. Baseline characteristics were comparable. Perioperative survival was similar (right ventricular dominant, 98%; non-right ventricular dominant, 100%; P = .51). The proportion of patients experiencing death or heart transplantation was 8.7%, and the rate of Fontan failure was 11.8% during a median follow-up of 4.5 years (interquartile range, 0.3-9.8 years). Right ventricular-dominant patients had reduced transplant-free survival (10-year estimates: 80% [95% CI, 70%-91%] vs 92% [95% CI, 83%-100%]; P = .04) and freedom from Fontan failure (73% [95% CI, 62%-86%] vs 92% [95% CI, 83%-100%]; P = .04). Multiphase hazard modeling resolved 2 risk phases. The early phase spanned from surgery to approximately 6 months afterward. The late phase spanned from approximately 6 months after surgery onward. In multivariable analysis, right ventricular dominance was an independent risk factor for death or heart transplantation (parameter estimate, 1.3 ± 0.6; P = .04) and Fontan failure (1.1 ± 0.5; P = .04) during the second phase, with no significant first-phase risk factors. CONCLUSIONS Right ventricular dominance was associated with long-term complications after Fontan procedures, including mortality, heart transplantation, and Fontan failure. This cohort may benefit from heightened surveillance in a multidisciplinary Fontan clinic after the perioperative period.
Collapse
Affiliation(s)
- Steven W Thornton
- Duke University School of Medicine, Durham, North Carolina; Duke Congenital Heart Surgery Research and Training Laboratory, Durham, North Carolina.
| | - James M Meza
- Duke Congenital Heart Surgery Research and Training Laboratory, Durham, North Carolina; Division of Cardiovascular and Thoracic Surgery, Duke University Hospitals, Durham, North Carolina
| | - Neel K Prabhu
- Duke University School of Medicine, Durham, North Carolina; Duke Congenital Heart Surgery Research and Training Laboratory, Durham, North Carolina
| | - Lillian Kang
- Department of Surgery, Duke University Hospitals, Durham, North Carolina; Duke Congenital Heart Surgery Research and Training Laboratory, Durham, North Carolina
| | - Mary E Moya-Mendez
- Duke University School of Medicine, Durham, North Carolina; Duke Congenital Heart Surgery Research and Training Laboratory, Durham, North Carolina
| | - Lauren E Parker
- Duke University School of Medicine, Durham, North Carolina; Duke Congenital Heart Surgery Research and Training Laboratory, Durham, North Carolina
| | - Gregory A Fleming
- Department of Pediatrics, Duke University Hospitals, Durham, North Carolina; Duke Congenital Heart Surgery Research and Training Laboratory, Durham, North Carolina
| | - Joseph W Turek
- Duke Congenital Heart Surgery Research and Training Laboratory, Durham, North Carolina; Division of Cardiovascular and Thoracic Surgery, Duke University Hospitals, Durham, North Carolina
| | - Nicholas D Andersen
- Duke Congenital Heart Surgery Research and Training Laboratory, Durham, North Carolina; Division of Cardiovascular and Thoracic Surgery, Duke University Hospitals, Durham, North Carolina
| |
Collapse
|
6
|
Brimmer S, Ji P, Birla AK, Keswani SG, Caldarone CA, Birla RK. Recent advances in biological pumps as a building block for bioartificial hearts. Front Bioeng Biotechnol 2023; 11:1061622. [PMID: 36741765 PMCID: PMC9895798 DOI: 10.3389/fbioe.2023.1061622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 01/04/2023] [Indexed: 01/22/2023] Open
Abstract
The field of biological pumps is a subset of cardiac tissue engineering and focused on the development of tubular grafts that are designed generate intraluminal pressure. In the simplest embodiment, biological pumps are tubular grafts with contractile cardiomyocytes on the external surface. The rationale for biological pumps is a transition from planar 3D cardiac patches to functional biological pumps, on the way to complete bioartificial hearts. Biological pumps also have applications as a standalone device, for example, to support the Fontan circulation in pediatric patients. In recent years, there has been a lot of progress in the field of biological pumps, with innovative fabrication technologies. Examples include the use of cell sheet engineering, self-organized heart muscle, bioprinting and in vivo bio chambers for vascularization. Several materials have been tested for biological pumps and included resected aortic segments from rodents, type I collagen, and fibrin hydrogel, to name a few. Multiple bioreactors have been tested to condition biological pumps and replicate the complex in vivo environment during controlled in vitro culture. The purpose of this article is to provide an overview of the field of the biological pumps, outlining progress in the field over the past several years. In particular, different fabrication methods, biomaterial platforms for tubular grafts and examples of bioreactors will be presented. In addition, we present an overview of some of the challenges that need to be overcome for the field of biological pumps to move forward.
Collapse
Affiliation(s)
- Sunita Brimmer
- Laboratory for Regenerative Tissue Repair, Texas Children’s Hospital, Houston, TX, United States,Center for Congenital Cardiac Research, Texas Children’s Hospital, Houston, TX, United States,Division of Congenital Heart Surgery, Texas Children’s Hospital, Houston, TX, United States
| | - Pengfei Ji
- Laboratory for Regenerative Tissue Repair, Texas Children’s Hospital, Houston, TX, United States,Center for Congenital Cardiac Research, Texas Children’s Hospital, Houston, TX, United States,Division of Congenital Heart Surgery, Texas Children’s Hospital, Houston, TX, United States
| | - Aditya K. Birla
- Laboratory for Regenerative Tissue Repair, Texas Children’s Hospital, Houston, TX, United States,Center for Congenital Cardiac Research, Texas Children’s Hospital, Houston, TX, United States
| | - Sundeep G. Keswani
- Laboratory for Regenerative Tissue Repair, Texas Children’s Hospital, Houston, TX, United States,Center for Congenital Cardiac Research, Texas Children’s Hospital, Houston, TX, United States,Department of Surgery, Baylor College of Medicine, Houston, TX, United States,Division of Pediatric Surgery, Department of Surgery, Texas Children’s Hospital, Houston, TX, United States
| | - Christopher A. Caldarone
- Center for Congenital Cardiac Research, Texas Children’s Hospital, Houston, TX, United States,Division of Congenital Heart Surgery, Texas Children’s Hospital, Houston, TX, United States,Department of Surgery, Baylor College of Medicine, Houston, TX, United States,Division of Pediatric Surgery, Department of Surgery, Texas Children’s Hospital, Houston, TX, United States
| | - Ravi K. Birla
- Laboratory for Regenerative Tissue Repair, Texas Children’s Hospital, Houston, TX, United States,Center for Congenital Cardiac Research, Texas Children’s Hospital, Houston, TX, United States,Division of Congenital Heart Surgery, Texas Children’s Hospital, Houston, TX, United States,Department of Surgery, Baylor College of Medicine, Houston, TX, United States,Division of Pediatric Surgery, Department of Surgery, Texas Children’s Hospital, Houston, TX, United States,*Correspondence: Ravi K. Birla,
| |
Collapse
|
7
|
Emani SM. Management of the Borderline Left Heart and Alternatives to Fontan. World J Pediatr Congenit Heart Surg 2022; 13:645-649. [PMID: 36053112 DOI: 10.1177/21501351221116278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Management of borderline left heart can be divided into single ventricle and biventricular repair strategies. Recently, the strategy of left heart recruitment has been applied to select patients. Left heart recruitment strategies and alternatives to Fontan circulation are reviewed. The criteria utilized for decision-making include size and function of left heart structures as well as hemodynamics measured by cardiac catheterization.
Collapse
Affiliation(s)
- Sitaram M Emani
- Department of Cardiac Surgery, 1862Children's Hospital Boston, Boston, MA, USA
| |
Collapse
|